A collaboration between the Garvan Institute of Medical Research and Peter Mac has shed light on how cancer cells can precisely control their behaviour through the action of tiny micro-RNAs. They found these small molecules can make a very big impact on whether a cancer cell lives or dies.
Peter Mac Chief Executive Dale Fisher is supporting the next generation of Australian women in senior and leadership positions. On Friday 1 December, Dale Fisher will be an official Mentor at the Mentor Walks Australia event in Melbourne.
A new support service has been launched at Peter Mac in response to the unique challenges faced by patients who are also parents of young or adolescent children. Parent Matters - a joint initiative of Peter Mac and CanTeen – responds to the profound and long-lasting impact that cancer can have on children as roles and family relationships change to adjust to the presence of the disease.
Congratulations to Peter Mac’s Chief Executive Dale Fisher who was this week awarded a Monash University Fellowship. The Fellowship is an honour awarded by the university in recognition of the achievements that alumni have made, and continue to make, through their professional distinction and outstanding service.
Professor Michael Friedlander has a unique perspective on ovarian cancer treatment and research gained from 35 years as one of Australia’s leading cancer clinician-researchers. On Thursday, 9 November, Prof Friedlander will give the Penny Taylor Oration – a free community forum held at Peter Mac annually to support awareness and research into ovarian cancer.
Peter Mac researchers, Assoc Prof Sarah-Jane Dawson, Prof Monica Slavin, Assoc Prof Phil Darcy, Dr Benjamin Teh and Dr Jason Trubiano, have each received highly prestigious awards from the National Health and Medical Research Council (NHMRC), CSL and Biomedical Research Victoria (BioMedVic).
Research presented this week at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides.
A team of Australian researchers, led by Peter Mac’s Dr Shahneen Sandhu, has been awarded a $1M “Challenge Award” from the US’ Prostate Cancer Foundation to undertake a first-in-field trial for a novel combination of radionucleic therapy and a targeted agent in men with aggressive prostate cancer.
Using a second generation immunotherapy drug for the long-term management of a common type of blood cancer has been shown to give patients more durable control of their cancer. A clinical trial has shown patients who took the antibody drug Obinutuzumab together with and after their chemotherapy had a 34% reduced risk of their disease getting worse, over three years.
A key factor in the progression of cancer is its ability to recruit the body’s own blood and lymphatic vessels to provide nutrients and a gateway to spread to other sites. A Peter Mac-led research team has for the first time extensively mapped the signalling networks associated with the specialised cells which line these vessels - endothelial cells.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.